Related Experiment Video
Updated: May 26, 2026
08:42
Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China
Published on: February 11, 2022
Primary benign cardiac tumours: long-term results
Davide Pacini1, Lucio Careddu, Antonio Pantaleo
1Department of Cardiac Surgery, S Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. dav.pacini@gmail.com
Summary
Surgical treatment of primary benign heart tumors yields good outcomes. Close follow-up is crucial for detecting myxoma recurrence and associated extracardiac tumors.
Area of Science:
- Cardiology
- Cardiac Surgery
- Oncology
Background:
- Primary heart tumors are rare and exhibit diverse histological types.
- This study reviews a 35-year experience with primary benign cardiac tumors.
Purpose of the Study:
- To analyze the outcomes of surgical treatment for primary benign cardiac tumors.
- To evaluate the long-term survival, recurrence rates, and associated extracardiac tumors.
Main Methods:
- A retrospective review of patients with primary cardiac tumors from 1974 to 2009 at the University of Bologna.
- Benign tumors were classified as myxomas (94 cases) and non-myxomas (13 cases).
- Surgical resection was performed in all but one case.
Main Results:
- In-hospital mortality was 3% for myxomas and 8% for non-myxomas.
- Long-term survival at 20 years was 68% for myxomas and 100% for non-myxomas.
- Tumor recurrence occurred in 4% of myxoma cases; extracardiac tumors were frequently associated with myxomas.
Conclusions:
- Surgical intervention for primary cardiac tumors offers favorable short- and long-term results.
- Patient's preoperative condition significantly impacts mortality and morbidity.
- Mandatory follow-up is essential for detecting tumor recurrence and associated extracardiac tumors.
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:23Mitral Stenosis II: Clinical features and Diagnostic Tests
Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...